Liver transplantation in hepatitis B core–negative recipients using livers from hepatitis B core–positive donors: A 13‐year experience

The use of livers from hepatitis B surface antigen–negative (HBsAg − )/hepatitis B core antibody–positive (HBcAb + ) donors in liver transplantation (LT) for HBsAg − /HBcAb − recipients is still controversial because of a lack of standard antiviral prophylaxis and long‐term follow‐up. We present our 13‐year experience with the use of HBcAb + donor livers in HBcAb − recipients. Patients received prophylaxis with hepatitis B immunoglobulin at the time of LT and then lamivudine daily. De novo hepatitis B virus (HBV) was defined as positive HBV DNA detection. Between January 1999 and December 2010, 1013 adult LT procedures were performed at our center. Sixty‐four HBsAg − /HBcAb − patients (6.3%) received an HBsAg − /HBcAb + liver. All donor sera were negative for HBcAb immunoglobulin M and HBV DNA. The mean follow‐up was 48.8 ± 40.1 months (range = 1.2‐148.8). Both the patient survival rates and the graft survival rates were 92.2% and 69.2% at 1 and 5 years, respectively. No graft losses or deaths were related to de novo HBV. Nine of the 64 patients (14.1%) developed de novo HBV. The mean time from LT to de novo HBV was 21.4 ± 26.1 months (range = 10.8‐92.8 months). De novo HBV was successfully treated with adefovir or tenofovir. In conclusion, HBcAb + allografts can be safely used in HBcAb − recipients without increased mortality or graft loss. Lifelong prophylaxis, continuous surveillance, and compliance are imperative for success. Should a de novo infection occur, our experience suggests that a variety of treatments can be employed to salvage the graft and obtain serum HBV DNA clearance. Liver Transpl 19:611–618, 2013 . © 2013 AASLD.